open access
SAPIEN 3 Ultra — Design and procedural features of a new balloon-expandable valve
open access
Abstract
Abstract
Keywords
transcatheter heart valve, TAVI
About this articleTitle
SAPIEN 3 Ultra — Design and procedural features of a new balloon-expandable valve
Journal
Issue
Pages
194-196
Published online
2019-09-26
DOI
10.5603/CJ.a2019.0096
Pubmed
Bibliographic record
Cardiol J 2020;27(2):194-196.
Keywords
transcatheter heart valve
TAVI
Authors
Radosław Parma
Damian Hudziak
Grzegorz Smolka
Radosław Gocoł
Andrzej Ochała
Wojciech Wojakowski
References (4)- Solomonica A, Choudhury T, Bagur R. Newer-generation of Edwards transcatheter aortic valve systems: SAPIEN 3, Centera, and SAPIEN 3 Ultra. Expert Rev Med Devices. 2019; 16(2): 81–87.
- Daubert MA, Weissman NJ, Hahn RT, et al. Long-Term Valve Performance of TAVR and SAVR: A Report From the PARTNER I Trial. JACC Cardiovasc Imaging. 2016 [Epub ahead of print].
- Kapadia SR, Leon MB, Makkar RR, et al. PARTNER trial investigators. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015; 385(9986): 2485–2491.
- Hahn RT, Pibarot P, Leipsic J, et al. The Effect of Post-Dilatation on Outcomes in the PARTNER 2 SAPIEN 3 Registry. JACC Cardiovasc Interv. 2018; 11(17): 1710–1718.